OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
SANTA MONICA, Calif., Feb. 24, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (877) 301-8565
Live (International): (678) 562-4240
Confirmation number: 45173015
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
